ETOP IBCSG Partners Foundation

Bern’s Mayor Marieke Kruit endorses the #IBCSGPinkLadies at the 2025 Swiss Women’s Run. “The Pink Ladies are highlighting an important issue. Women with breast cancer deserve our solidarity. I thank the Pink Ladies for their invaluable commitment.” — Marieke Kruit, Mayor of Bern

Back in Zurich for another exceptional @etop_ibcsg workshop, now focusing on T-cell engagers (TCE) and their unprecedented benefit in #SCLC. An amazing group of colleagues who paved preclinical/clinical development discussed the presence and the future of TCEs. Watch this…

@triparnasen gives a masterclass presentation on SCLC subtypes, their biological significance & implication for possible treatments @etop_ibcsg

Delighted to be part of ETOP workshop on T-cell Engagers Summary of DLL3 targeting agents 👉 Incredible number of Tarlatamab studies underway 👉 Competitors coming: Obrixtamig trial portfolio equally active 👉 More agents too: especially MK6070 Exciting prospects

Fantastic first day at the ETOP Workshop on T Cell Engagers. Reviewing the data, previewing the future, devising ways to overcome barriers to implementation. Great to engage with friends in Zurich! @etop_ibcsg

Superb @etop_ibcsg T-cell engager workshop exploring next steps in thoracic tumors & academic trials. Stellar talks, including - TCEs in thoracic Onc @peters_solange - Genomics of SCLC #RamGovindan - Biomarkers in SCLC @triparnasen Thanks to the scientific committee #LCSM

REMINDER: Apply now for our 14th ETOP Residential Workshop. Deadline is 31st July.

ADOPT-lung TiP paper out in @LungCaJournal doi.org/10.1016/j.lung… Neo-adjuvant nivolumab has shown sig. OS benefit in CheckMate-816. The need for 1 additional year of adjuvant immunotherapy is being debated. This trial aims to investigate the added value of adjuvant durvalumab

This Wednesday, 2nd July at 13h CEST! Register now, if not already done so! register.gotowebinar.com/register/76848…

We are happy to announce that the ETOP Slide deck of the 2025 ASCO Annual Meeting is now available online: etop.ibcsg.org/research-and-n…

ETOP Slide Deck of 2025 ASCO Annual Meeting and Webinar Reminder - mailchi.mp/f40410330833/w…

3rd year of a fantastic deep-dive workshop into #ADC development across solid tumors organized by @etop_ibcsg amazing hosts Rolf Stahel and @peters_solange which is becoming a tradition! Happy to be invited among a stellar faculty of global experts across disciplines and…

#SOFT&TEXT trials are the result of over 20 years of collaboration. Thank you to patients and their families, HC providers, study chairs and committees, collaborators, the cross-Atlantic groups & the funders. @etop_ibcsg @theNCI @BCRFcure #ASCO25

.@nicogirardcurie presents NIVOTHYM, nivo-ipi cohort thymic B3/carcinoma P2. N=51, 86% carcinoma Did not meet 1o of 6moPFS rate 60% mPFS 3.1mo ORR 16% 29% G3+ irAEs Efficacy results not better than nivo mono cohort previously reported @etop_ibcsg @EORTC

#ASCO25: Assessment of #breastcancer Index benefit in #premenopausal pts receiving OFS-containing adjuvant #endocrinetherapy was compared btw #SOFT&TEXT cohorts and validation of the prognostic performance of BCI was conducted, go check Poster #150 @etop_ibcsg @oreganruth

Oral abstract session at #ASCO25 with 15-y follow-up data from @etop_ibcsg SOFT & TEXT trials…proper risk stratification is needed to optimize adjuvant endocrine therapy in premenopausal women with #BreastCancer @OncoAlert

Read here our ETOP IBCSG Partners Foundation Annual Report 2024, which highlights the Foundation's many activities and achievements. This year has been defined by remarkable progress as well as persistent challenges in the global fight against cancer. etop.ibcsg.org/about-us/etop-…

New publication out on the IBCSG 61-20/ BCT 1902 Neo-N trial, sponsored by @BCTrialsANZ : thelancet.com/journals/lanon…

New publication out on the IBCSG 35-07 SOLE trial: ejcancer.com/article/S0959-…

#ESMObreast25 has come to a close with major insights from BIG studies. From long-term survival data to fertility and patient-reported outcomes, here are key takeaways from the event. #Aphinitytrial #Optimatrial #Positivetrial #ALTTOtrial #Pallastrial #ALPHABETtrial #BCSM